

Information Governance

Robert Dolan House
9 Alie Street
London
E1 8DE

Email elft.foi@nhs.net

Website: <https://www.elft.nhs.uk>

18 January 2024

Our reference: FOI DA5098

I am responding to your request for information received 6 December 2023 and clarified on 21 December. This has been treated as a request under the Freedom of Information Act 2000.

I am now enclosing a response which is attached to the end of this letter. Please do not hesitate to contact me on the contact details above if you have any further queries.

Yours sincerely,

Information Rights Coordinator

If you are dissatisfied with the Trust's response to your FOIA request then you should contact us and we will arrange for an internal review of this decision.

If you remain dissatisfied with the decision following our response to your complaint, you may write to the Information Commissioner for a decision under Section 50 of the Freedom of Information Act 2000. The Information Commissioner can be contacted at:

Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF

Tel: 0303 123 1113
Web: www.ico.org.uk

Please note that the data supplied is not allowed to be re-used and/or published without the explicit consent of East London NHS Foundation Trust. Please contact the signatory to request permission if this is your intention



We promise to work together creatively to: learn
'what matters' to everyone, achieve a better quality
of life and continuously improve our services.
We care . We respect . We are inclusive

Interim Chief Executive Officer: Lorraine Sunduza
Chair: Eileen Taylor

Request: This is a freedom of information request under the Freedom of Information Act 2000. Please provide the following information you have pertaining to NHS Trust unlicensed medicine expenditure.

Question 1: What is the total value of spend by your NHS Trust on unlicensed medication (i.e. Special Order, Drug Tariff Special Order, Part VIID Drug Tariff Special Order) that have a BNF liquid formulation (e.g. liquid, solution, suspension)? Please provide this information on a volume and value basis for the following years - Apr-20 to Mar-21, Apr-21 to Mar-22, Apr-22 to Mar-23. (please fill in the tables below).

Note: Value of spend to mean either net ingredient cost or actual cost. Please state which you have used below. Actual cost would be the total cost to NHS commissioners whereas NIC is the cost at list price excluding VAT.

Answer: Please see table below:

Total Value	Total spend / cost on liquid unlicensed products procured		
Type	Apr-20 to Mar-21	Apr-21 to Mar-22	Apr-22 to Mar-23
Special Order	Data not available - the pharmacy stock system only provides accessible data for current and previous financial year.	Data not available - the pharmacy stock system only provides accessible data for current and previous financial year.	£64,198.23
Drug Tariff Special Order			
Part VIID Drug Tariff Special Order			
Other Special			

Question 2: What is the total volume by your NHS Trust on unlicensed medication (i.e. Special Order, Drug Tariff Special Order, Part VIID Drug Tariff Special Order) that have a BNF liquid formulation (e.g. liquid, solution, suspension)? Please provide this information on a volume and value basis for the following years - Apr-20 to Mar-21, Apr-21 to Mar-22, Apr-22 to Mar-23.

Clarification - Volume can either refer to total mls or units depending on which is easiest to analyse from a data pov.

Answer: Please see table below:

Total Volume	Total volume of liquid unlicensed products procured		
Type	Apr-20 to Mar-21	Apr-21 to Mar-22	Apr-20 to Mar-21
Special Order	Data not available - the pharmacy stock system only provides accessible data for current and previous financial year.	Data not available - the pharmacy stock system only provides accessible data for current and previous financial year.	248600ml, total 1577 packs (bottles)
Drug Tariff Special Order			
Part VIID Drug Tariff Special Order			
Other Special			

Question 3: Do you outsource the manufacturing of liquid unlicensed products?

Answer: Yes.



We promise to work together creatively to: learn 'what matters' to everyone, achieve a better quality of life and continuously improve our services.
We care . We respect . We are inclusive

Interim Chief Executive Officer: Lorraine Sunduza
Chair: Eileen Taylor

Question 4: If no to question 3 (use of outsourcing providers), what proportion of the products that you manufacture in-house are aseptically compounded rather than terminally sterilised?

Answer: Not applicable.

Question 5: If yes to question 3 (use of outsourcing providers), what is the total value of spend by provider? Please provide this information for the following years - Apr-20 to Mar-21, Apr-21 to Mar-22, Apr-22 to Mar-23. (please fill in the tables below).

Note: If more than 10 providers are used, please only detail spend with the top 10.

Answer: Please see table below:

Outsourcing provider <i>(fill in empty rows with provider name, add rows if required)</i>	Total value of liquid specials procured from each provider		
	Apr-20 to Mar-21	Apr-21 to Mar-22	Apr-22 to Mar-23
Rosemont Pharmaceuticals	Data not available - the pharmacy stock system only provides accessible data for current and previous financial year.	Data not available - the pharmacy stock system only provides accessible data for current and previous financial year.	£64,198.23



We promise to work together creatively to: learn 'what matters' to everyone, achieve a better quality of life and continuously improve our services.
We care . We respect . We are inclusive

Interim Chief Executive Officer: Lorraine Sunduza
Chair: Eileen Taylor